These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24398568)

  • 21. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line.
    Ghilardi N; Skoda RC
    Mol Endocrinol; 1997 Apr; 11(4):393-9. PubMed ID: 9092791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokines and soluble cytokine receptors in pleural effusions from septic and nonseptic patients.
    Marie C; Losser MR; Fitting C; Kermarrec N; Payen D; Cavaillon JM
    Am J Respir Crit Care Med; 1997 Nov; 156(5):1515-22. PubMed ID: 9372669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agents against cytokine synthesis or receptors.
    Yamagata T; Ichinose M
    Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
    Frey K; Zivanovic A; Schwager K; Neri D
    Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins.
    LaMarre J; Wollenberg GK; Gonias SL; Hayes MA
    Lab Invest; 1991 Jul; 65(1):3-14. PubMed ID: 1712874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet.
    Siebler J; Wirtz S; Weigmann B; Atreya I; Schmitt E; Kreft A; Galle PR; Neurath MF
    Gastroenterology; 2007 Jan; 132(1):358-71. PubMed ID: 17241885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity.
    Gillies SD
    Protein Eng Des Sel; 2013 Oct; 26(10):561-9. PubMed ID: 24025193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural analysis of IL-10 and Type I interferon family members and their complexes with receptor.
    Walter MR
    Adv Protein Chem; 2004; 68():171-223. PubMed ID: 15500862
    [No Abstract]   [Full Text] [Related]  

  • 30. Bacterial endotoxin regulation of cytokine receptors on murine bone marrow cells: in vivo and in vitro study.
    Shieh JH; Peterson RH; Moore MA
    J Immunol; 1994 Jan; 152(2):859-66. PubMed ID: 8283056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiotrophin-like cytokine labelling using Bir A biotin ligase: a sensitive tool to study receptor expression by immune and non-immune cells.
    Cognet I; Guilhot F; Gabriac M; Chevalier S; Chouikh Y; Herman-Bert A; Guay-Giroux A; Corneau S; Magistrelli G; Elson GC; Gascan H; Gauchat JF
    J Immunol Methods; 2005 Jun; 301(1-2):53-65. PubMed ID: 15936768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Receptors and mechanisms of neurotropic effects of cytokines and growth factors].
    Oleinik AA; Vast'ianov RS
    Usp Fiziol Nauk; 2008; 39(2):47-57. PubMed ID: 18540452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
    Liu S; Riley J; Rosenberg S; Parkhurst M
    J Immunother; 2006; 29(3):284-93. PubMed ID: 16699371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Setting the cytokine trap for autoimmunity.
    Dinarello CA
    Nat Med; 2003 Jan; 9(1):20-2. PubMed ID: 12514715
    [No Abstract]   [Full Text] [Related]  

  • 35. Selection of non-competitive leptin antagonists using a random nanobody-based approach.
    Zabeau L; Verhee A; Catteeuw D; Faes L; Seeuws S; Decruy T; Elewaut D; Peelman F; Tavernier J
    Biochem J; 2012 Jan; 441(1):425-34. PubMed ID: 21851341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptin-Activity Modulators and Their Potential Pharmaceutical Applications.
    Greco M; De Santo M; Comandè A; Belsito EL; Andò S; Liguori A; Leggio A
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokine-receptor interactions as drug targets.
    Schreiber G; Walter MR
    Curr Opin Chem Biol; 2010 Aug; 14(4):511-9. PubMed ID: 20619718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection and manipulation of live antigen-expressing cells using conditionally stable nanobodies.
    Tang JC; Drokhlyansky E; Etemad B; Rudolph S; Guo B; Wang S; Ellis EG; Li JZ; Cepko CL
    Elife; 2016 May; 5():. PubMed ID: 27205882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unraveling the molecular mechanism governing the tissue specific expression of IFNλR1.
    Akhtar H; Hamming OJ; Jan SU; Akhtar S; Terczyn' ska-Dyla E; Siupka P; Shafique A; Hartmann R; Sadia H
    Pak J Pharm Sci; 2016 May; 29(3):795-9. PubMed ID: 27166550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral nanobody-IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice.
    Lutz EA; Jailkhani N; Momin N; Huang Y; Sheen A; Kang BH; Wittrup KD; Hynes RO
    PNAS Nexus; 2022 Nov; 1(5):pgac244. PubMed ID: 36712341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.